Update: New results boost NuQ for lung and CRC
VolitionRx recently released data for NuQ in colorectal and lung cancer, which both exceeded results from previous trials. In colorectal cancer (CRC), the test when adjusted for age detected 91% of tumors with 90% specificity in its first completed prospective study, unlike previous retrospective studies. The company also released encouraging interim lung cancer data detecting 93% of tumors with 91% specificity using the NuQ test in combination with smoking history, which positions the test as one of the most accurate non-invasive lung cancer diagnostics.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.